See more : Chaozhou Three-Circle (Group) Co.,Ltd. (300408.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Pulike Biological Engineering, Inc. (603566.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulike Biological Engineering, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- South China Holdings Company Limited (0413.HK) Income Statement Analysis – Financial Results
- 55 North Mining Inc. (FFF.CN) Income Statement Analysis – Financial Results
- Minupar Participações S.A. (MNPR3.SA) Income Statement Analysis – Financial Results
- Aurum Pacific (China) Group Limited (8148.HK) Income Statement Analysis – Financial Results
- Fuji Corporation (6134.T) Income Statement Analysis – Financial Results
Pulike Biological Engineering, Inc. (603566.SS)
About Pulike Biological Engineering, Inc.
Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.25B | 1.23B | 1.10B | 928.51M | 663.19M | 608.06M | 529.90M | 583.10M | 478.14M | 475.69M | 472.08M | 417.53M | 412.62M | 292.35M | 266.43M |
| Cost of Revenue | 488.40M | 457.34M | 379.95M | 331.25M | 257.64M | 200.23M | 167.84M | 167.31M | 130.40M | 119.14M | 124.78M | 120.08M | 127.11M | 83.82M | 73.73M |
| Gross Profit | 764.30M | 770.68M | 718.62M | 597.26M | 405.56M | 407.83M | 362.06M | 415.79M | 347.73M | 356.55M | 347.30M | 297.44M | 285.52M | 208.54M | 192.71M |
| Gross Profit Ratio | 61.01% | 62.76% | 65.41% | 64.32% | 61.15% | 67.07% | 68.33% | 71.31% | 72.73% | 74.95% | 73.57% | 71.24% | 69.20% | 71.33% | 72.33% |
| Research & Development | 107.30M | 90.46M | 85.57M | 114.84M | 90.82M | 73.46M | 6.20M | 58.46M | 41.76M | 36.87M | 32.79M | 26.03M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 29.75M | 35.96M | 31.62M | 28.62M | 21.43M | 19.01M | 48.94M | 46.34M | 30.27M | 34.14M | 29.91M | 25.86M | 60.16M | 61.49M | 32.99M |
| Selling & Marketing | 352.03M | 364.70M | 300.04M | 211.00M | 164.60M | 147.11M | 143.26M | 131.04M | 107.41M | 106.87M | 96.71M | 84.99M | 84.73M | 49.83M | 46.05M |
| SG&A | 477.69M | 400.66M | 331.66M | 239.62M | 186.02M | 166.12M | 192.20M | 177.38M | 137.68M | 141.01M | 126.62M | 110.85M | 144.88M | 111.32M | 79.03M |
| Other Expenses | -13.71M | 58.32M | 28.59M | 20.36M | 32.34M | 16.48M | 25.44M | 37.92M | 14.29M | 9.64M | 23.07M | 12.72M | 5.04M | 11.15M | 52.27K |
| Operating Expenses | 571.28M | 549.44M | 445.82M | 374.81M | 309.18M | 281.28M | 272.42M | 250.43M | 199.94M | 197.54M | 175.46M | 150.46M | 148.41M | 113.31M | 80.90M |
| Cost & Expenses | 1.06B | 1.01B | 825.77M | 706.06M | 566.82M | 481.51M | 440.26M | 417.74M | 330.35M | 316.69M | 300.24M | 270.54M | 275.51M | 197.12M | 154.63M |
| Interest Income | 4.13M | 4.45M | 2.50M | 3.65M | 6.24M | 5.90M | 3.77M | 4.36M | 4.95M | 1.50M | 476.20K | 660.71K | -0.09 | -0.90 | -0.13 |
| Interest Expense | 1.12M | 728.29K | 226.06K | 75.15K | 549.27K | 374.92K | 3.71M | 4.31M | 4.90M | 1.46M | 152.72K | 3.90M | 5.14M | 868.40K | 1.53M |
| Depreciation & Amortization | 92.73M | 75.33M | 59.46M | 51.21M | 50.38M | 41.91M | 37.36M | 32.53M | 31.90M | 31.00M | 24.59M | 22.68M | 4.54M | 4.29M | 3.91M |
| EBITDA | 288.26M | 253.29M | 352.24M | 312.81M | 179.99M | 147.20M | 130.65M | 201.43M | 178.60M | 190.00M | 216.80M | 185.86M | 137.11M | 97.25M | 112.99M |
| EBITDA Ratio | 23.01% | 22.59% | 31.25% | 35.09% | 26.52% | 34.46% | 24.66% | 34.54% | 37.82% | 40.63% | 46.59% | 43.04% | 33.18% | 33.26% | 42.41% |
| Operating Income | 193.01M | 183.21M | 284.58M | 246.59M | 106.88M | 136.74M | 107.89M | 183.05M | 154.30M | 157.61M | 169.04M | 141.88M | 132.36M | 92.95M | 109.09M |
| Operating Income Ratio | 15.41% | 14.92% | 25.91% | 26.56% | 16.12% | 22.49% | 20.36% | 31.39% | 32.27% | 33.13% | 35.81% | 33.98% | 32.08% | 31.79% | 40.94% |
| Total Other Income/Expenses | 1.60M | 803.72K | -408.80K | 14.94M | 10.30M | 16.48M | 25.44M | 37.83M | 13.97M | 9.43M | 23.02M | 9.18M | 4.86M | 10.55M | 52.08K |
| Income Before Tax | 194.61M | 184.01M | 284.18M | 260.00M | 117.19M | 153.22M | 133.33M | 220.90M | 168.54M | 167.03M | 192.06M | 151.06M | 137.22M | 103.50M | 109.14M |
| Income Before Tax Ratio | 15.54% | 14.98% | 25.87% | 28.00% | 17.67% | 25.20% | 25.16% | 37.88% | 35.25% | 35.11% | 40.68% | 36.18% | 33.26% | 35.40% | 40.96% |
| Income Tax Expense | 20.10M | 9.90M | 40.04M | 32.26M | 7.94M | 17.60M | 19.15M | 32.90M | 26.80M | 26.78M | 29.20M | 21.85M | 21.85M | 19.51M | 16.38M |
| Net Income | 174.52M | 167.82M | 244.14M | 227.74M | 109.25M | 135.61M | 114.19M | 188.00M | 141.74M | 140.26M | 162.86M | 129.21M | 115.38M | 83.99M | 92.76M |
| Net Income Ratio | 13.93% | 13.67% | 22.22% | 24.53% | 16.47% | 22.30% | 21.55% | 32.24% | 29.64% | 29.48% | 34.50% | 30.95% | 27.96% | 28.73% | 34.82% |
| EPS | 0.50 | 0.54 | 0.78 | 0.72 | 0.34 | 0.42 | 0.36 | 0.59 | 0.49 | 0.59 | 0.68 | 0.54 | 0.48 | 0.35 | 0.39 |
| EPS Diluted | 0.50 | 0.54 | 0.78 | 0.72 | 0.34 | 0.42 | 0.36 | 0.59 | 0.49 | 0.59 | 0.68 | 0.54 | 0.48 | 0.35 | 0.39 |
| Weighted Avg Shares Out | 349.03M | 322.43M | 314.64M | 316.31M | 321.50M | 321.50M | 317.18M | 318.65M | 289.27M | 239.76M | 239.50M | 239.28M | 240.37M | 240.37M | 240.37M |
| Weighted Avg Shares Out (Dil) | 349.03M | 322.43M | 314.64M | 316.31M | 321.50M | 322.89M | 317.18M | 318.65M | 289.27M | 239.76M | 239.50M | 239.28M | 240.37M | 240.37M | 240.37M |
No news found for: 603566.SS
Source: https://incomestatements.info
Category: Stock Reports